SPECIAL ARTICLE

ESMO recommendations on the standard methods to detect *NTRK* fusions in daily practice and clinical research

C. Marchiò[1,2], M. Scaltriti[3,4], M. Ladanyi[3], A. J. Iafrate[5,6], F. Bibeau[7], M. Dietel[8], J. F. Hechtman[3], T. Troiani[9], F. López-Rios[10], J.-Y. Douillard[11], F. Andrè[12]* & J. S. Reis-Filho[3]

[1]Department of Medical Sciences, University of Turin, Turin; [2]Division of Pathology, Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Italy; [3]Department of Pathology; [4]Human Oncology & Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York; [5]Department of Pathology, Massachusetts General Hospital, Boston; [6]Department of Pathology, Harvard Medical School, Boston, USA; [7]Department of Pathology, Caen University Hospital, Caen, France; [8]Institute of Pathology, Charité, University Medicine Berlin, Berlin, Germany; [9]Medical Oncology, Department of Precision Medicine, University of Campania "Luigi Vanvitelli", Naples, Italy; [10]Pathology & Targeted Therapies Laboratory, HM Sanchinarro University Hospital, Madrid, Spain; [11]European Society for Medical Oncology, Lugano, Switzerland; [12]Department of Medical Oncology, INSERM Unit 981, Institut Gustave Roussy, Villejuif, France

*Correspondence to: Prof. Fabrice André, ESMO Head Office – Scientific and Medical Division, Via Ginevra 4, Lugano CH-6962, Switzerland. Tel: +41-91-973-1999; Fax: +41-91-973-1902; E-mail: education@esmo.org

Background: *NTRK1*, *NTRK2* and *NTRK3* fusions are present in a plethora of malignancies across different histologies. These fusions represent the most frequent mechanism of oncogenic activation of these receptor tyrosine kinases, and biomarkers for the use of TRK small molecule inhibitors. Given the varying frequency of *NTRK1/2/3* fusions, crucial to the administration of NTRK inhibitors is the development of optimal approaches for the detection of human cancers harbouring activating *NTRK1/2/3* fusion genes.

Materials and methods: Experts from several Institutions were recruited by the European Society for Medical Oncology (ESMO) Translational Research and Precision Medicine Working Group (TR and PM WG) to review the available methods for the detection of NTRK gene fusions, their potential applications, and strategies for the implementation of a rational approach for the detection of *NTRK1/2/3* fusion genes in human malignancies. A consensus on the most reasonable strategy to adopt when screening for *NTRK* fusions in oncologic patients was sought, and further reviewed and approved by the ESMO TR and PM WG and the ESMO leadership.

Results: The main techniques employed for *NTRK* fusion gene detection include immunohistochemistry, fluorescence *in situ* hybridization (FISH), RT-PCR, and both RNA-based and DNA-based next generation sequencing (NGS). Each technique has advantages and limitations, and the choice of assays for screening and final diagnosis should also take into account the resources and clinical context.

Conclusion: In tumours where *NTRK* fusions are highly recurrent, FISH, RT-PCR or RNA-based sequencing panels can be used as confirmatory techniques, whereas in the scenario of testing an unselected population where *NTRK1/2/3* fusions are uncommon, either front-line sequencing (preferentially RNA-sequencing) or screening by immunohistochemistry followed by sequencing of positive cases should be pursued.

Key words: NTRK1, NTRK2, NTRK3, immunohistochemistry, fluorescence *in situ* hybridisation, next-generation sequencing

Introduction

Neurotrophic tropomyosin-related kinases (NTRKs, or the commonly used alias TRKs) constitute a receptor tyrosine kinase family of neurotrophin receptors involved in neuronal development, including the growth and function of neuronal synapses and memory development [1]. After embryogenesis, TRK expression is limited primarily to the nervous system, where these kinases help regulate pain, proprioception, appetite and memory, and participate in the protection of neurons after ischaemia or other

types of injury [1, 2]. The three TRK family members described, namely NTRK1 (also known as TRKA), NTRK2 (also known as TRKB) and NTRK3 (also known as TRKC), that can be found in multiple tissue types (supplementary Table S1, available at *Annals of Oncology* online) and are encoded by the *NTRK1*, *NTRK2* and *NTRK3* genes, respectively. The TRK receptors are composed of an extracellular domain for ligand binding, a transmembrane portion and an intracellular domain with a kinase domain. Oligomerisation of the receptors and phosphorylation of specific tyrosine residues in the intracytoplasmic kinase domain are triggered when the ligand binds to the receptor, thus leading to the activation of signal transduction pathways, which results into proliferation, differentiation and survival in normal and neoplastic neuronal cells [3].

NTRK point mutations and indels have been described in various tumour types, including ovarian, colorectal, and lung cancers, as well as melanomas and myeloid leukaemia [4–8]. It should be noted, however, that the potential role of these mutations in promoting tumorigenesis and cancer progression is poorly understood. In fact, the vast majority of *NTRK* mutations are not known to be clinically actionable; however, some may constitute mechanisms of resistance to TRK inhibitors [9]. One in-frame deletion (ΔTRKA) and a splice variant (TRKAIII) in *NTRK1* have been reported as oncogenic in acute myeloid leukaemia and neuroblastoma, respectively [10, 11]. On the other hand, oncogenic fusions involving *NTRK1, NTRK2* and *NTRK3* have been reported in a plethora of malignancies across different histologies and represent the key mechanisms of oncogenic TRK activation [12]. These oncogenic fusions create chimeric genes in which the 3′ region of the *NTRK* gene is joined with a 5′ sequence of a fusion partner gene, and may stem from intra-chromosomal or inter-chromosomal rearrangements [12, 13]. Despite the multitude of 5′ fusion gene partners, *NTRK1/2/3* fusion genes share key characteristics, including the fact that the resulting genetic chimera uniformly contains the *NTRK* kinase domain with the critical tyrosine docking sites (Figure 1), and results in a constitutively activated and overexpressed TRK kinase [12]. These fusion genes have been shown to possess oncogenic properties, including the induction of cancer cell proliferation and activation of critical cancer-related downstream signalling, such as the mitogen-activated protein kinase (MAPK) and PI3K/AKT pathways [12, 17–19]. Many 5′ gene partners (at least 25) have been described; nevertheless, all rearrangements share an in-frame, intact TRK kinase domain [12, 20, 21].

Fusion genes affecting *NTRK1/2/3* are highly recurrent in certain rare malignancies. The best known form of *NTRK* fusion gene is the *ETV6-NTRK3*, which is present in >95% of secretory carcinomas of the breast [22] and of the salivary glands (i.e. mammary analogue secretory carcinoma of the salivary glands) [23], congenital fibrosarcoma [24] and cellular mesoblastic nephromas [25]. This fusion gene is the product of the t(12;15)(p13;q25) chromosomal translocation, which results in a chimeric transcript encompassing exon 4, 5 or 6 of *ETV6* and the kinase domain of *NTRK3* [22]. The *ETV6–NTRK3* fusion gene leads to constitutive activation of the TRKC kinase domain, with downstream activation of the PI3K/AKT and MAPK pathways [18, 26]. The *ETV6–NTRK3* fusion gene is also found in a small subset of acute myeloid leukaemia [27, 28], but the breakpoints are distinct from those found in solid malignancies. *NTRK1/2/3*

fusion genes have also been detected in small subsets of common tumour types, and, in this context, the fusions typically occur in a mutually exclusive fashion with other strong mitogenic drivers, i.e. genetic alterations affecting the most common driver genes belonging to the MAPK signalling pathway (e.g. *KRAS*, *NRAS* and *BRAF*) [29–32]. They have also been reported as significantly more frequently encountered in microsatellite instability (MSI)-high tumours in the context of colorectal carcinoma patients [31]. Interestingly, a recent study has shown that the association between *NTRK* fusions with MSI-high colorectal carcinomas seems to be strictly connected with MLH1 deficiency associated with *MLH1* promoter hypermethylation in the context of a non-Lynch syndrome scenario [32].

NTRK1/2/3 gene fusions have emerged as new targets for cancer therapy as they can be successfully inhibited by targeted kinase inhibitors [20, 21, 33, 34]. Of note, responses have been documented irrespective of the 5′ gene partner and in a histology-agnostic fashion [9, 20, 33, 34]. Several compounds targeting TRKs are currently being explored in clinical trials and, notably, one of these compounds, larotrectinib (VITRAKVI®), has received accelerated approval by the United States Food and Drug Administration (FDA) for adult and paediatric solid tumours with an *NTRK* fusion without known resistance mutations [35]. In addition, entrectinib has received breakthrough designation status by the United States FDA for the treatment of cancers harbouring *NTRK* fusions. Hence, there is an active interest in clinical oncology for *NTRK* fusions, which has prompted an urgent need to define the routine diagnostic testing to identify gene fusions as a companion diagnostic method to support clinical decision in this context. Therefore, the European Society for Medical Oncology (ESMO) Translational Research and Precision Medicine Working Group (TR and PM WG) launched a collaborative project to review the available methods that can be used to detect *NTRK1/2/3* gene fusions.

NTRK1/2/3 fusion gene detection

A wide array of different techniques can be employed in the detection of *NTRK1/2/3* fusions (supplementary Figure S1, available at *Annals of Oncology* online). Historically, gene fusions have been assayed by fluorescence *in situ* hybridisation (FISH) and reverse transcriptase (RT)-PCR, and FISH assays for the detection of the *ETV6–NTRK3* fusion gene are commercially available. However, given the multitude of 5′ partners involved in *NTRK1/2/3* fusion genes, assays that allow for the detection of multiple variants in a single test, including next-generation sequencing (NGS)-based RNA and DNA approaches, have been widely used in large academic centres in North America. The adoption of these NGS-based methods in other contexts has proven challenging, given the costs for the implementation and running of the assay, limited reimbursement by public or private payors, need for bioinformatics expertise and relatively longer turnaround time (1–3 weeks).

As a general approach, one could consider that in those malignancies where the *NTRK* fusions are described as pathognomonic or highly recurrent genetic alterations, such as the *ETV6–NTRK3* fusion gene in secretory carcinoma of the breast and of the salivary glands, congenital fibrosarcomas and cellular mesoblastic

Figure 1. Schematic representation of the different *NTRK* fusion genes, illustrating the *NTRK* domains maintained across fusion genes regardless of the 5′ partner. Tumour types in which the different fusions have been described are reported. Data are extrapolated from Vaishnavi et al. [12], Prabhakaran et al. [14], Qaddoumi et al. [15], Milione et al. [16] and Zehir et al. [13]. Fusion proteins are not drawn to scale. GB, glioblastoma; CNS, central nervous system; CRC, colorectal carcinoma; CUP, cancer of unknown primary; KD, kinase domain; MASC, mammary analogue of secretory carcinoma (i.e. secretory carcinoma of the salivary glands); PTC, papillary thyroid carcinoma; TM, transmembrane. *Colorectal carcinoma, papillary thyroid carcinoma, paediatric glioma, sarcoma, lung adenocarcinoma. **Astrocytoma, including pylocitic astrocytoma, paediatric high-grade glioma and adult glioblastoma. ***Secretory breast carcinoma, secretory carcinoma of the salivary glands, acute myeloid leukaemia, papillary thyroid carcinoma, paediatric gliomas, congenital fibrosarcoma, cellular mesoblastic nephroma and colorectal carcinomas.

Table 1. Summary of main features, strengths and weaknesses of all available techniques to detect *NTRK* rearrangements

Method	Sensitivity	Specificity	Detection of all fusion genes	Detection of partner	Detection of expression	Screening
IHC	High[a]	High[b]	Yes	No	Yes	Yes
FISH[c]	High	High	One per probe	No	No	No
RNA seq NGS	High	High	Yes	Yes	Yes	Yes
DNA seq[c]	Moderate	High	Yes	Yes	No	Yes

[a]False negatives reported mainly in *NTRK3* fusions.
[b]In the absence of smooth muscle/neuronal differentiation.
[c]Detected rearrangements by DNA-based assays may not result in fusions, correlation with surgical pathology and predicted transcript (for sequencing) is needed.

nephromas [22] (supplementary Table S1, available at *Annals of Oncology* online), the detection of the fusion gene could be accomplished by FISH or RT-PCR. Conversely, in those neoplasms where a limited proportion of cases is expected to harbour an *NTRK1/2/3* fusion and the gene partner is unknown (supplementary Table S1, available at *Annals of Oncology* online), assays allowing for the detection of fusion genes in an agnostic manner would be indicated, either in the form of front-line NGS testing or by using a two-step approach involving a screening by immunohistochemistry (IHC) followed by NGS of cases expressing TRKA/B/C.

From a technical standpoint, all the techniques have strengths and weaknesses (Table 1), as discussed in detail here below.

In situ assays

Immunohistochemistry. Different antibodies are available to detect TRK expression in tissue samples. There are antibodies directed against specific NTRK proteins (TRKA or TRKB) [16, 30, 36], antibodies targeting an amino acid sequence common to TRKA, TRKB and TRKC (pan-TRK antibodies) [37–40] or a pan-TRK antibody cocktail [41]. Positive controls for IHC include the cell lines KM12 (*TPM3-NTRK1*) [36], MO-91 (*ETV6-NTRK3*) and CUTO-3.29 (*MPRIP-NTRK1*) [42], and formalin-fixed, paraffin-embedded (FFPE) cell pellets can be used as external controls in immunohistochemical runs [43]. Peripheral nerves can serve as internal control, if present in the

stroma (supplementary Figure S2, available at *Annals of Oncology* online). Non-neoplastic tissues (skin, blood vessels, inflammatory cells) serve as negative internal controls [38].

The pattern of TRK expression detected by IHC can be variable in intensity and subcellular localisation (supplementary Figure S2, available at *Annals of Oncology* online). There are data supporting the notion that the subcellular distribution of the chimeric protein may vary with the 5′ fusion gene partner. For instance, when using a pan-TRK antibody five *LMNA–NTRK1* fusion-positive neoplasms displayed nuclear membrane accentuation [39], which was also observed in an *LMNA–NTRK1* fusion-positive uterine sarcoma assessed with an anti-TRKA antibody [37]. When using a panTRK antibody, *TM3/4* fusion-positive tumours displayed cellular membrane accentuation [39], and an uterine sarcoma harbouring *TPR–NTRK1* fusion displayed strong and diffuse cytoplasmic expression with dot-like aggregates as well as rare nuclear expression and accentuation of the nuclear envelope [37]. Finally, half (3/6) of *ETV6–NTRK3* fusions displayed nuclear staining [39]. It should be emphasised, however, that further characterisation of the subcellular localisation according to the fusion gene partners is required before these patterns are adopted for diagnostic purposes.

Given the restricted expression of TRKA, TRKB and TRKC in adult tissues (i.e. smooth muscle, testes and neuronal components [44–46]), IHC has been proven highly sensitive (from 95% [39] to 100% [37]) and specific (from 93% [37] to 100% [39]) for the detection of *NTRK* fusions. It should be noted, however, that values for sensitivity and specificity reported so far derive from data on relatively small cohorts. Further validation in large cohorts will likely be more informative in the next future.

Hechtman et al. [39] analysed *NTRK* fusion-positive and *NTRK* fusion-negative cases, using DNAseq and RNAseq methods (see below). Pan-TRK IHC was positive in 20/21 cases with *NTRK* fusion transcripts. The discordant negative case was a mismatch repair-deficient colorectal carcinoma with an *ETV6–NTRK3* fusion. For all 20 RNAseq-negative cases concordant IHC results were observed. In addition, Chiang et al. [37] reported on four *NTRK* fusion-positive uterine sarcomas that showed features of fibrosarcoma and all displayed pan-TRK staining, with three of them also showing concurrent TRKA staining. In that study, 97 uterine spindle cell leiomyosarcomas were analysed: four fusion-negative cases (as assessed by FISH and/or NGS) displayed weak and diffuse cytoplasmic TRKA expression, and 2 featured strong and diffuse cytoplasmic pan-TRK expression. Rudzinski et al. [38] observed a 97% sensitivity and a 98% specificity for the presence of an *NTRK* fusion when employing a pan-TRK antibody, whereas TRKA IHC (EP1058Y) was 100% sensitive and 63% specific. Consistent with Hechtman et al. [39], Rudzinski et al. [38] also identified a single false negative *ETV6-NTRK3*-rearranged tumour when using pan-TRK antibodies; however, this tumour displayed diffuse, strong positivity for TRKA. Due to the lack of monoclonal anti-TRKC antibodies, it is uncertain as to whether these *ETV6–NTRK3* fusions that were independently detected in the two studies were indeed false negative IHC results rather than fusions that did not result in translation of the protein.

Taken together, these data suggest that pan-TRK IHC is a valuable tool to identify *NTRK*-rearranged neoplasms, and has several advantages as to: (i) it has relatively high sensitivity and specificity;

(ii) it represents a rapid method that can be easily employed in different laboratory environments with a quick turnaround time; (iii) it is able theoretically to detect only transcribed and translated fusion proteins; (iv) it is relatively inexpensive and requires limited material.

However, in addition to the known limitations of immunohistochemical analyses in general, that include also possible issues related to the pre-analytical phase, IHC for TRKA, TRKB and TRKC has important caveats. First, a subset of cases, in particular those with smooth muscle and neuronal differentiation, expressing TRK proteins lack any identifiable fusions. Secondly, the interpretation of IHC results may prove challenging in tissues where TRKs are physiologically expressed. Thirdly, a subset of fusion gene positive cases (mainly *NTRK3*) lack TRK protein expression as defined by IHC [39]. Fourthly, there are no monoclonal, c-terminus TRKC antibodies, i.e. specific to *NTRK3* fusions, currently commercially available. Finally, the expression of the receptors is not diagnostic of an *NTRK1/2/3* fusion gene; it merely suggests that a fusion gene is likely present. Hence, some further considerations are required. In general, tumours harbouring *NTRK3* fusions have much weaker staining for pan-TRK than tumours with *NTRK1/NTRK2* fusions. This differential expression, as well as the presence of nuclear staining in *NTRK3*-rearranged tumours, may be useful for directing subsequent molecular testing strategies [38]. A possible algorithm in the use of pan-TRK IHC as a surrogate marker for *NTRK* fusions has been proposed: moderate to strong diffuse cytoplasmic pan-TRK IHC staining can be considered as a surrogate of the presence of *NTRK1/NTRK2* fusions (in the absence of muscle or neural differentiation of the lesion) and nuclear pan-TRK IHC can be considered a surrogate of *NTRK3* fusions. For tumours with only weak cytoplasmic expression of pan-TRK, an *NTRK* fusion should be confirmed by other molecular/cytogenetic methods to ensure that a fusion is present in patients being considered for targeted therapeutic agents [38].

One of the approaches that has emerged consists of using IHC first, as a screening tool, followed by an RNA-based NGS approach to detect the specific fusion [40, 41]. The purpose of IHC screening is to distinguish in a rapid manner between patient specimens that are pan-negative for NRTKs and those that demonstrate a weak to strong level of tumour staining, which may harbour gene fusions. However, the overall cost-effectiveness of this method is debated, due to the rarity of *NTRK* fusions (<0.5% of cancers overall), in particular if additional targets are investigated. Outside of the rare tumour types with high-prevalence of *ETV6–NTRK3* fusions, up-front screening with NGS panels are ultimately the least expensive approach to uncover actionable driver alterations including the investigation of possible *NTRK* fusions. Nonetheless, this two-step approach has allowed for the enrolment of patients in basket trials, such as the STARTRK trials [20]. In the context of STARTRK-2, a basket study of entrectinib for the treatment of patients with solid tumours harbouring *NTRK*1/2/3, *ROS1* or *ALK* fusion genes (ClinicalTrials.gov Identifier: NCT02568267), it is specified that for patients enrolled via local molecular testing, an archival or fresh tumour tissue was required to be submitted for independent central molecular testing at a central CLIA-certified laboratory. There are preliminary data reported by Potts et al. on the detection of *NTRK*, *ROS1* and *ALK* gene fusions in gastrointestinal

tumour patients [40] with a pan-TRK antibody used to perform IHC locally and an AMP-based NGS assay (Archer FusionPlex^{TM}) used for confirmation of positives. The IHC positivity average rate was 8% across 15 tumour locations. Out of 157 gastrointestinal samples, no instances were detected where IHC yielded a negative result and fusion genes were detected by NGS (100% negative predictive value). In a study evaluating a cohort of samples of multiple histologies ($n = 636$) Murphy et al. [41] used an antibody cocktail consisting of monoclonal antibodies targeting Pan-TRK, ROS1 and ALK with confirmation using anchored multiplex PCR (AMP) targeted RNAseq (Archer FusionPlex^{TM} gene fusion assay). Approximately 30% showed positive staining and were tested by NGS. In a subgroup of 192 samples of colorectal, thyroid and lung cancers the pan-TRK IHC test had a 100% negative predictive value for gene fusion detection and the overall prevalence of the fusion gene within the IHC positive population was 9%, demonstrating an enrichment of fusion-positive samples within a population of clinical samples (versus the 4% frequency without the application of IHC screening).

As the prevalence reported here in these two studies is higher than that reported in the literature for these histologies (supplementary Table S1, available at *Annals of Oncology* online), we cannot exclude that somehow the cohorts analysed were a priori 'pre-enriched' for fusions.

Fluorescence in situ *hybridisation.* FISH is a commonly used method for detecting chromosomal rearrangements and has been effectively used to detect *ALK, ROS1* and *RET* fusions in solid tumours. Either fusion or break-apart probes (supplementary Figure S3, available at *Annals of Oncology* online) can be used to investigate for the presence of *NTRK1, NTRK2* or *NTRK3* fusions; nevertheless, split-apart fusion probes are invariably easier in FFPE samples. Similar to IHC, FISH cannot ascertain the 5′ partner or whether the fusion results in a productive in-frame chimeric transcript. Given that a multiplex FISH requires a great deal of experience in its interpretation, three separate FISH assays would have to be run in parallel, which become expensive and time consuming. FISH, however, can be very effective at identifying the presence of the *ETV6–NTRK3* fusion gene in the tumour types where it is highly prevalent.

The studies reported so far have used a wide array of probes detecting *NTRK* fusions, some constructed as home-brew assays [17, 29, 37, 47], others being commercially available specific break-apart probe kits mainly for *NTRK1* [16, 42] or *NTRK3*. When investigating *ETV6–NTRK3* fusions, there is also the possibility to use a mixed break-apart probe allowing detection of *ETV6, NTRK3* and other 13 genes breaks [48]. For instance, this approach was used in a study analysing *ETV6–NTRK3* fusion transcripts in 25 cases of secretory carcinoma of the salivary glands and the split-apart signals of the *NTRK3* gene were detected in 16 of the 25 cases [48]. In three cases, the tissue was not analysable, and in two other cases analysis could not be carried out because of lack of FFPE tissue. In the four remaining cases lacking *NTRK3* split-apart signals and *ETV6* split-positive, the fusion of *ETV6* gene to a non-*NTRK3* gene was suggested. To pursue possible fusion partners in these cases, involvement of *NTRK1* and *NTRK2* genes was examined, however, neither *NTRK1* nor *NTRK2* split-apart signals were identified.

Recommendations for scoring are those generally accepted for FISH for fusion gene detection. Sections should be 4 μm thick to avoid artefactual split-apart signals. Scoring should be carried out by counting the number of fluorescent signals in at least 50 randomly selected non-overlapping tumour cell nuclei. Scoring by more than one observer is recommended. A cut-off value for gene break is set at 10% or 15% (i.e. cases can be considered as harbouring a gene fusion if >10% or >15% of nuclei display 'split-apart signals'; red and green signals should be separated by a distance greater than the size of two hybridisation probe signals) [23, 49].

Albeit being a robust technology for the detection of highly recurrent known fusion genes and confirmation of potential fusion genes, the utility of FISH for screening cancers with *NTRK1/2/3* fusions is limited, given the multitude of partners involved, the expertise required and its labour-intensive nature.

In vitro nucleic acid-based assays

In assays based on nucleic acids extracted from tumour tissues, an evaluation of tumour cellularity and specimen adequacy is of utmost importance. Additional pre-analytic parameters are equally important, including warm and cold ischaemia, length of fixation and chemical properties of the fixatives employed. Therefore, robust approaches tailored for FFPE tissue samples are essential. RNA and DNA NGS assays can detect *de novo* fusion genes involving *NTRK1, NTRK2* and *NTRK3*, and define the 5′ partner. It should be noted, however, that for most of these assays bioinformatics experience is required, and the turnaround times can be lengthier than those of more targeted molecular assays [39].

Reverse transcription-PCR. RT-PCR analyses of *NTRK* fusions have been reported in thyroid neoplasms [50, 51], glioblastomas [52], congenital fibrosarcomas [53], secretory carcinoma of the salivary glands [23, 48] and of the breast [54, 55]. Furthermore, RT-PCR has been used as an orthogonal validation method in studies exploring the genetic landscape of subgroups of neoplasms by high-throughput techniques [52].

Skalova et al. [48] analysed a series of 25 morphologically and immunophenotypically confirmed secretory carcinoma of the salivary glands with the absence of classical, exon 5-exon 15, *ETV6–NTRK3* fusion transcript as detected by standard RT-PCR. The classical fusion transcript was analysed by a more sensitive nested RT-PCR. In addition, atypical exons 4–14 *ETV6-NTRK3* fusion transcripts, as well as possible combinations of exons involved in classical and atypical junction, were analysed by nested RT-PCR and/or RT-PCR. In four cases, the classical fusion transcript was found by nested RT-PCR. Five other cases harboured atypical, exons 4–14 or exons 5–14, *ETV6-NTRK3* fusion transcripts detected by both nested and/or standard RT-PCR. The rest of the cases remained negative on RT-PCR. FISH with *NTRK3* break-apart probes was also carried out and a *NTRK3* gene split was detected in 16/25 cases. For five cases, the tissue was not analysable due to technical issues, but in the four remaining cases no evidence of *NTRK3* fusion was detected and *ETV6* split-apart signals were observed, thus suggesting the fusion of *ETV6* with a non-*NTRK3* gene. Regrettably, these cases were not

subjected to NGS to elucidate the potential 3′ partners of these potential fusion genes.

RNA NGS assays. Given the chimeric nature of the transcripts stemming from gene fusions, RNA sequencing constitutes an approach for the *de novo* detection of fusion genes that are transcribed. The primary concern with handling RNA is related to its labile nature, especially when dealing with archival FFPE samples. Highly damaged RNA is composed of fragments that are too short to be informative and/or will hamper library preparation and subsequent sequencing. RNA quality assessment is therefore a crucial step in this process in order to discriminate possible false negative results and to enable reproducibility of the test [41].

Although studies where whole transcriptome RNA sequencing to detect fusions affecting the *NTRK* genes are on record [1, 56], more common is the use of targeted assays. In recent years, AMP, for which commercial ready-to-use kits as well customisable assays are available, has become a widely adopted methodology for fusion gene detection. Owing to the initial adapter ligation step that facilitates priming without a priori knowledge of the gene fusion partner, the AMP method has been shown to have high technical sensitivity and specificity even in FFPE-derived RNA samples. In these assays, the sequencing library targets known fusion exons in multiple oncogenes including *NTRK1* and/or *NTRK3* [29, 37, 39, 47], or all of the three members of the *NTRK* family [16, 37, 39].

The impact of RNA quality was assessed in one study analysing 44 archival cases (infantile fibrosarcoma, congenital mesoblastic nephroma, secretory carcinoma of the salivary glands and secretory breast carcinoma) with sufficient tissue to be tested with NGS by an Archer DX AMP assay. Only 23/44 passed pre-sequencing quality control thresholds. Nevertheless, it should be mentioned that the likelihood that a case would fail quality control increased with sample aging, a feature expected to impact an assay using RNA extracted from FFPE tissue [29].

AMP has been employed also in larger studies aiming at screening for the presence of known fusion exons in multiple oncogenes: for instance, a panel including *ALK, ROS1, RET* and *NTRK1* fusion has been used in a phase I dose escalation study of entrectinib in adult patients with locally advanced or metastatic non-small-cell lung carcinomas (NCT02097810). In this study, out of the 1378 enrolled cases, two patients harboured *NTRK1* gene fusions (0.1%, 95% confidence interval 0.01%, 0.5%): a *TPM3–NTRK1* fusion previously described and a fusion transcript containing sequence from *SQSTM1* (sequestosome 1) and *NTRK1* [47].

In addition to the AMP technology, other NGS platforms can offer the possibility to test for *NTRK* fusions. These include the GeneTrails Solid Tumor Fusion Gene Panel (Knight Diagnostic Laboratories), designed to detect fusions involving 20 target genes including *NTRK1, NTRK2, NTRK3* [57]; the Universal Fusion/Expression Profile (Neogenomics), an assay capable of detecting different classes of genomic abnormalities such as fusion transcripts and transcriptomic gene expression levels in 1385 genes (*NTRK1, NTRK2, NTRK3* included); and the Oncomine assays (ThermoFisher Scientific), which cover fusion variants including *NTRK1, NTRK2* and *NTRK3* [58].

These panels require different amounts of RNA input. The choice of the technology must therefore take into account the amount of tissue available for testing.

Targeted next-generation DNA sequencing assays. Targeted NGS assays consist of panels of selected genes of interest where either all of the exons or hotspot regions only in selected exons for each gene are investigated. Several companies as well as academic centres have developed such assays, which can exploit distinct types of chemistry for sequencing. Some of the commercially available targeted sequencing panels offer the possibility to detect fusion genes and there are many examples where targeted DNA panels have been employed to detect *NTRK* fusions.

Some studies have been based on the Memorial Sloan Kettering Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT™) assay, a deep-coverage hybridisation capture-based assay encompassing the entire coding regions and selected intronic and regulatory regions of >400 key cancer genes [30, 39]. This tumour-profiling multiplex panel has been recently cleared by the United States FDA as an *in vitro* diagnostic test that can identify somatic genetic alterations. MSK-IMPACT™ can detect missense mutations, indels, copy number alterations and selected gene fusions. In this panel, probes for introns 3, and 7–12 of *NTRK1*, and intron 15 of *NTRK2* are included to detect fusions involving these 2 genes. In addition, probes for *ETV6* introns 4 and 5 are included to detect *ETV6-NTRK3* fusions. Of note, other introns affected by *NTRK* fusions could not be included because they are too large for a DNA-based capture approach (approximate upper limit: 25 kb). Zehir et al. [13] have reported on the use of MSK-IMPACT in a prospective clinical sequencing of unselected metastatic patients and *NTRK1* and *NTRK3* fusions were detected in 18 patients (0.2%), a subgroup of whom were subsequently enrolled in targeted clinical trials.

A study focussed on MSK-IMPACT applied to the analysis of 449 melanoma patients revealed four cases (0.9%) harbouring *NTRK* fusion genes; in three of these cases, the 3′ partner was *NTRK1*, whereas in the remaining melanoma, *NTRK2* was rearranged [30].

There are other DNA-targeted sequencing assays that can be employed in the detecting of *NTRK* fusions. Some examples include the UW Oncoplex and the UCSF500 Cancer Gene Panel, both using probes for exons and selected introns of *NTRK1, NTRK2* and *NTRK3*. Additional probes for *ETV6* exons and selected introns are included to detect *ETV6-NTRK3* fusions; the UW OncoPlex includes additional probes for selected exons and introns of *EML4* to detect *EML4-NTRK3* fusions [38]. In addition, the SmartGenomics Complete—(PathGroup) Expanded Solid Tumor, includes 160 genes profiled for mutations and 126 gene fusions. Finally, the FDA-approved FoundationOneCDx test (Foundation Medicine) allows for *NTRK* detection: it analyses 315 genes and selected fusions including those involving *NTRK1, NTRK2* and *NTRK3*. *NTRK* fusions can also be detected by FoundationOne®Heme, a DNA- and RNA-based NGS assay that analyses 236 cancer-related genes and 19 genes commonly rearranged in cancer. Foundation Medicine has reported their experience on 2031 tumour specimens from paediatric, adolescent and young adult patients affected by a variety of neoplastic conditions [leukaemia and solid tumours, including primary central nervous system (CNS) tumours] that were assayed with

FoundationOne®Heme in the course of clinical care. From this dataset, nine unique patients (0.44%) were identified to harbour *NTRK* fusions [59]. For four cases where a diagnosis of infantile fibrosarcoma was considered, FISH for *ETVT6-NTRK3* was carried out and showed negative results in three of them.

Other commercially available DNA- and RNA-based panels that can detect *NTRK* fusions are listed in supplementary Table S2, available at *Annals of Oncology* online.

Undoubtedly, DNA-based NGS has proven to be effective to detect gene rearrangements and predicted fusions; however, not all of the *NTRK* fusions can be practically detected using targeted assays, especially those fusions involving *NTRK2* and *NTRK3* where large intronic regions can render DNA-based detection challenging [9]. Furthermore, many of the *NTRK* fusions detected by DNA-based sequencing are of unknown functional significance, requiring confirmation by another assay [39]. Hence, DNA-based targeted sequencing assays are often supplemented with RNA-sequencing methods. As mentioned above, FoundationOne®Heme incorporates both DNA- and RNA-based NGS approaches, and the Archer DX AMP assays is currently run in parallel with MSK-IMPACT™ for selected patients.

On the other hand, in a study comparing RNA- and DNA-based NGS, 23 tumours of various histology where *NTRK* fusions had been identified on MSK-IMPACT were subjected to Archer RNA testing, which detected *NTRK* fusion transcripts in 21/23 cases. The two negative cases, a lung adenocarcinoma and a glioblastoma, both harboured a DNA level fusion that did not result in an RNA level fusion transcript (involving *NTRK1* exon 5/*P2RY8* exon2 and *NTRK3* exon 14/*ZNF710* exon exon1, respectively) nor show TRK protein expression as assessed by IHC with a Pan-TRK antibody [39]. This highlights the need for NTRK IHC or RNA-based confirmation in cases of unusual or atypical *NTRK* genomic fusions detected by DNA-based testing, as some of these may represent non-functional bystander fusions.

NanoString technology. This digital barcode technology allows direct multiplexed measurement of analytes by the detection of hundreds of unique transcripts in a single reaction with the ability to analyse DNA, RNA and protein even simultaneously [60]. No enzymes or library preparation are required to perform the assay. In terms of analysis of gene fusions, there is a commercially available ready-to-use nCounter Lung Fusion Panel, which includes 63 probes, namely 35 for specific fusion detection (including *CD74-NTRK1* and *MPRIP-NTRK1*), 24 for positional gene expression imbalance detection, and 4 internal reference genes. As an alternative, it is possible to design custom panels. To the best of our knowledge, no studies specifically for the detection of *NTRK1/2/3* fusion genes have been conducted so far by using this technique.

Circulating cell-free DNA/RNA testing for *NTRK* fusions

Peripheral blood might represent an alternative source of tumour-derived nucleic acids when a tumour specimen is not available. A number of DNA- or RNA-based NGS panels for the analysis of liquid biopsy are available. However, in most cases the coverage of *NTRK* fusions provided by these panels are limited.

For example, the current versions of the DNA-based panels Guardant360 and AVENIO Extended ctDNA Analysis Kits cover only *NTRK1* fusions. The Oncomine Pan-Cancer Cell-Free Assay uses a single library from circulating DNA and RNA, and can detect selected fusions of the *NTRK1* and *NTRK3* genes. The limitations of these assays must be taken into account when screening for *NTRK* fusions.

Clinical perspectives and ongoing trials

Identification of *NTRK* fusions across different tumour types allowed for therapeutic interventions that are 'age- and tumour-agnostic' and best exemplified by the design of 'basket trials' for molecularly defined subsets of patients [61]. Several tyrosine kinase inhibitors for TRKA, TRKB and/or TRKC are available and show a varying degree of activity towards actionable *NTRK* fusions (i.e. harbouring an in-frame and intact kinase domain). There are selective TRK inhibitors (larotrectinib) and multikinase inhibitors with anti-TRK activity [entrectinib, TPX-0005 (repotrectinib), crizotinib, cabozantinib, altiratinib, foretinib, ponatinib, nintedanib, merestinib, BAY2731954 (formerly known as LOXO-195), MGCD516, PLX7486, DS-6051b and TSR-011] (supplementary Table S3, available at *Annals of Oncology* online) [33].

Larotrectinib and entrectinib represent the two compounds that are furthest in clinical development so far. Larotrectinib (VITRAKVI®) has received accelerated approval by the United States FDA for adult and paediatric solid tumours with an *NTRK* fusion without known resistance mutations [35]. Entrectinib has received breakthrough designation status by the United States FDA for the treatment of cancers harbouring *NTRK* fusions.

Larotrectinib (LOXO-101) is a potent and highly selective small molecule inhibitor of all three TRK proteins and has been developed in parallel in adult and paediatric populations. It has been investigated in a phase I study (ClinicalTrials.gov Identifier: NCT02637687) [62], which provided the first proof of concept of safety and high response rates (tumour regressions in >90%) in infants, children and adolescents with *NTRK* fusion cancers, thus establishing *NTRK* fusions as a tractable target in paediatric patients with solid or CNS tumours [62]. *NTRK* fusion gene testing was carried out locally before enrolment, in a CLIA-certified laboratory, by FISH, RT-PCR or NGS. No central testing was carried out in this protocol. Patients who did not have tumour samples available for such analyses were considered not to have *NTRK* fusions.

Parallel trials focussed on both adult and paediatric populations reported response rates of ∼80% of cancers harbouring *NTRK* fusion genes (ClinicalTrials.gov numbers: NCT02122913, NCT02637687 and NCT02576431) [33] and *NTRK* fusion genes were detected by NGS following procedures and analytic pipelines established by each laboratory, or by FISH [33].

New data recently presented at ASCO further corroborate the tumour-agnostic efficacy and the favourable safety profile of larotrectinib in adult patients with *NTRK* fusion-positive cancers [63], as well as its efficacy in CNS disease [64].

The potent oral inhibitor of the tyrosine kinases TRKA/B/C, ROS1 and ALK, entrectinib (RXDX-101), has been evaluated in two phase I studies (ALKA-372-001 and STARTRK-1) in patients

with advanced or metastatic solid tumours, including patients with active CNS disease [20]. For patients enrolled via local molecular testing, an archival or fresh tumour tissue was required to be submitted for independent central molecular testing at Ignyta's CLIA laboratory post-enrolment. Entrectinib was shown to be well tolerated and active against those gene fusions in solid tumours, including in patients with primary or secondary CNS disease, given that entrectinib can cross the blood–brain barrier. The analysis of the phase II-eligible population from ALKA-372-001 or STARTRK-1 (25 assessable patients) showed objective response rates (using RECIST) ranging from 57% to 100% [20]. More recently, pooled data from STARTRK-2, STARTRK-1 and ALKA-372-001 led to an integrated analysis of a global population ($n = 54$ patients in total) that has confirmed the clinically meaningful, deep and durable systemic responses in patients with and without CNS metastases, showing a 57.4% objective response rate [34]. Moreover, very recent data reported at ASCO also provide further evidence of efficacy of entrectinib in CNS neoplastic lesions [65].

Ongoing, actively recruiting interventional phase I and II trials assessing the response rates of anti-TRKs are summarised in supplementary Table S3, available at *Annals of Oncology* online.

Clinical trials assessing the efficacy of TRK inhibitors have also given the chance to investigate potential side-effects that may arise from inhibition of the full-length TRK receptors in normal tissues. In theory, loss of normal regulation of TRKA, TRKB or TRKC receptor activity can result in numerous human diseases [12]. Nevertheless, the limited side-effect profile of larotrectinib reported so far and the tolerability demonstrated for entrectinib suggest that long-term administration of these agents is feasible. The most common treatment-related adverse events of grade 3 in severity are fatigue/asthenia (reported for both larotrectinib and entrectinib) [20, 34], weight increase (reported for both larotrectinib and entrectinib) [20, 34] and anaemia (reported for entrectinib) [34]. Other side-effects include paresthesias, dizziness, dysgeusia, diarrhoea, nausea, myalgias and arthralgias. Importantly, all related adverse events were reversible with dose modifications [20, 34].

Despite durable responses to TRK kinase-directed therapy in patients with *NTRK*-rearranged tumours, it is expected that acquired resistance to therapy will ultimately emerge in most patients [66]. Consistent with this expectation, previous reports have described the acquisition of secondary mutations in the TRK kinase domain after treatment with entrectinib in two patients: *NTRK1* G595R and G667C substitutions were identified in independent resistant clones from a patient with *LMNA–NTRK1* fusion-positive colorectal cancer, and a *NTRK3* G623R substitution (homologous to *TRKA* G595R) was identified in a patient with *ETV6–NTRK3* fusion-positive secretory carcinoma of the salivary glands [67, 68]. In this scenario of resistance mediated by recurrent kinase domain mutations, BAY2731954 (LOXO-195) is a selective TRK TKI whose activity against these acquired mutations was confirmed in enzyme- and cell-based assays and *in vivo* tumour models [66]. In addition, as clinical proof of concept, the first two patients with NTRK fusion-positive cancers who developed acquired resistance mutations on larotrectinib were treated with BAY2731954 on a first-in-human basis, utilising rapid dose titration guided by pharmacokinetic assessments [66]. Of note, this approach led to rapid tumour responses and extended the overall duration of disease control achieved with NTRK inhibition in both patients. As BAY2731954 seems to be able to circumvent therapy resistance in *NTRK* fusion-positive cancers that acquired *NTRK* solvent front mutations, sequential treatment with distinct TRK inhibitors may constitute a viable therapeutic option (see also supplementary Table S3, available at *Annals of Oncology* online).

Another emerging compound is TPX-0005 (repotrectinib), which was recently proved effective in overcoming resistance due to acquired solvent-front mutations involving *ROS1*, *NTRK1-3* and *ALK* [69], thus representing a therapeutic option for patients who have progressed on earlier-generation TKIs.

In the scenario of lack of clinical response during first line anti-NTRK treatment, testing for *NTRK* mutations is recommended.

As an additional perspective, it is important to note that TRK inhibitors have been administered so far mainly to patients with metastatic disease; however, the efficacy of larotrectinib has been assessed also on selected patients with locally advanced disease. Two children with locally advanced infantile fibrosarcoma of the knee experienced substantial tumour shrinkage, allowing more conservative surgery with curative intent [33]. These data highlight the possible benefits of neoadjuvant therapy for patients with non-metastatic cancers bearing *NTRK* fusions [33].

Discussion

NTRK fusions can be detected at high frequency in a handful of specific histologies, namely secretory carcinoma of the breast and of the salivary glands, congenital fibrosarcoma and cellular mesoblastic nephroma, or identified at low frequency in a plethora of malignancies, and define a unique molecular subgroup of advanced solid tumours that can be targeted by specific agents. TRK inhibition has been proven highly effective leading to durable responses that have been observed without regard to the age of the patient, tumour tissue and fusion gene partner. To advance with these promising agents, it is critical to define optimal approaches for the identification of *NTRK1/2/3* fusion genes. The main techniques used in *NTRK* fusion detection are IHC, FISH, RNA- and DNA-based NGS assays.

When using a diagnostic test to identify patient populations with low prevalence molecular alterations, efficiency and cost challenges should be considered. In this respect, pan-TRK IHC has been demonstrated to represent a time-efficient and reliable screen for the detection of *NTRK* fusions and a two-step approach could be considered in clinical trials as well as in clinical practice. In cases displaying any degrees of protein expression, a multigene panel would be recommended to confirm or disprove the suspected genetic alteration. Nevertheless, gene panels offer the possibility to assess a relatively high number of actionable genes in a single assay, thus providing a higher degree of detail in the genomic landscape of the neoplastic lesions under investigation that may be key to plan the best therapeutic strategy for individual patients if used front line. Among the different options of gene panels, with respect to detection of *NTRK* fusions targeted RNA-sequencing methods may represent the gold standard for screening, provided that the RNA quality is optimal. In addition, we should also consider that whenever tissue availability is limited, a DNA/RNA approach may be preferred if DNA and/or

Figure 2. Summary of the ESMO Translational Research and Precision Medicine Working Group recommendations. Following the review of the literature on the available methods for the detection of *NTRK* gene fusions, the working group has agreed on a strategy for the implementation of a rational approach for the detection of *NTRK1/2/3* fusion genes in human malignancies, as depicted here. In the scenario where the presence of an *NTRK* fusion needs to be confirmed (this happens for patients affected by tumours in which *NTRK* fusion are known to be highly prevalent if not pathognomonic of the lesion) any technique could work in principle, nevertheless the best options as confirmatory techniques are FISH, RT-PCR or RNA-based targeted panels. In the scenario where the challenge is the identification of *NTRK* fusions in an unselected population, the possibility to use an NGS targeted panel (DNA- or RNA-based) that reliably detects *NTRK* fusions would be ideal. In particular, if the RNA quality is optimal targeted RNA sequencing methods may represent the gold standard for screening. If an *NTRK* fusion is identified, then the most exhaustive approach would include the use of IHC to confirm protein expression of the detected *NTRK* fusions, as the protein kinase is the pharmacological target. Alternatively, a 'two-step approach' could be considered, which includes IHC first and confirmation of any positivity detected with IHC by NGS (a service that could be externalised). *This population would be likely represented by 'any malignancy at an advanced stage, in particular if it has been proven wild type for other known genetic alterations tested in routine practice, and especially if diagnosed in young patients'.

RNA has already been extracted and is available due to other molecular tests already carried out on that tissue; IHC could be used to confirm the presence of the fusion.

Following the review of the literature on the available methods for the detection of *NTRK* gene fusions, the ESMO TR and PM WG recommendations for the implementation of a rational approach for the detection of *NTRK1/2/3* fusion genes in human malignancies are summarised in Figure 2 and include:

1. In case *NTRK* fusions need to be assayed in a specific histological tumour type, where *NTRK* genes are known to be highly recurrently rearranged with specific partners (histology-based/confirmation-approach), any method is applicable as long as validated in a CLIA laboratory. In this scenario, FISH with specific probes or nested RT-PCR represent perhaps the most cost-effective assays. Another increasingly used method is targeted RNAseq.
2. In case *NTRK* fusions need to be screened in an unselected population (histology-agnostic screening approach):
   a. Scenario A—no availability of a targeted sequencing assay (multigene panel): perform IHC (if no smooth muscle or neuronal differentiation is present) and send to

external sequencing any detected positivity (two-step approach).
   b. Scenario B—availability of a targeted sequencing assay (multigene panel): depending on the workload and cost-efficacy analyses carried out at each Institution, perform either front-line sequencing assay or adopt a two-step approach (IHC followed by targeted sequencing). If front-line sequencing is feasible, RNA sequencing methods represent the gold standard for screening, provided that the RNA quality is optimal. Nevertheless, we should acknowledge that the most exhaustive approach would be to: (i) use targeted DNA sequencing assay (multigene panel) upfront in all patients; (ii) for mitogenic driver-negative patients, perform targeted RNAseq (multigene panel); (iii) use IHC to confirm protein expression of *NTRK* fusions, as we should keep in mind that the protein kinase is the pharmacological target.

A final consideration should be dedicated to the definition of the population that should be tested. At present, systematic analyses of large cohorts of metastatic cancer patients for the presence of *NTRK1/2/3* fusion genes across cancer types have yet to be carried out. Therefore, phenotypic features of cancers harbouring

NTRK1/2/3 fusion genes have yet to be fully characterised. Some guidelines, and in particular those by the National Comprehensive Cancer Network on non-small-cell lung cancer, have already included a recommendation for *NTRK* gene fusion testing in patients with metastatic disease [70].

Based on these premises we believe that, outside those tumour types where *NTRK* fusions are expected at high frequency, a more conservative approach for the time being should be applied not to miss patients harbouring these targetable genetic alterations. Therefore, we would argue that the population to be tested should be represented by 'any malignancy at an advanced stage, in particular if it has been proven wild type for other known genetic alterations tested in routine practice, and especially if diagnosed in young patients'.

Disclosure

CM has received personal/consultancy fees from Axiom Healthcare Strategies, Cor2Ed, Bayer and Daiichi-Sankyo. MS received research funds from Puma Biotechnology, Daiichi-Sankyo, Immunomedics and Menarini Ricerche, honoraria from ADC Pharma and Menarini Ricerche and is a cofounder of Medendi Medical Travel. AJI is a founder and equity holder in ArcherDx, has received research funds from Blueprint Medicines, and is a consultant for Chugai, DebioPharm, Constellation, Roche and Pfizer. ML has received advisory board compensation from Boehringer Ingelheim, AstraZeneca, Bristol-Myers Squibb, Takeda and Bayer, clinical research support from LOXO Oncology, and pre-clinical research support from Helsinn Healthcare. JFH has received honoraria from Medscape, Axiom Biotechnologies and Cor2Ed, as well as research funding from Bayer. FL-R has received research funding from Thermo Fisherand Roche, as well as honoraria from Bayer, Thermo Fisher and Roche. JSR-F reports personal/consultancy fees from VolitionRx, Page.AI, Goldman Sachs, Grail, Ventana Medical Systems, Roche and Genentech. All remaining authors have declared no conflicts of interest.

References

1. Stransky N, Cerami E, Schalm S et al. The landscape of kinase fusions in cancer. Nat Commun 2014; 5: 4846.
2. Chao MV. Neurotrophins and their receptors: a convergence point for many signalling pathways. Nat Rev Neurosci 2003; 4(4): 299–309.
3. Nakagawara A. Trk receptor tyrosine kinases: a bridge between cancer and neural development. Cancer Lett 2001; 169(2): 107–114.
4. Geiger TR, Song JY, Rosado A, Peeper DS. Functional characterization of human cancer-derived TRKB mutations. PLoS One 2011; 6(2): e16871.
5. Marchetti A, Felicioni L, Pelosi G et al. Frequent mutations in the neurotrophic tyrosine receptor kinase gene family in large cell neuroendocrine carcinoma of the lung. Hum Mutat 2008; 29(5): 609–616.
6. Tomasson MH, Xiang Z, Walgren R et al. Somatic mutations and germline sequence variants in the expressed tyrosine kinase genes of patients with de novo acute myeloid leukemia. Blood 2008; 111(9): 4797–4808.
7. Harada T, Yatabe Y, Takeshita M et al. Role and relevance of TrkB mutations and expression in non-small cell lung cancer. Clin Cancer Res 2011; 17(9): 2638–2645.
8. Miranda C, Mazzoni M, Sensi M et al. Functional characterization of NTRK1 mutations identified in melanoma. Genes Chromosomes Cancer 2014; 53(10): 875–880.
9. Cocco E, Scaltriti M, Drilon A. NTRK fusion-positive cancers and TRK inhibitor therapy. Nat Rev Clin Oncol 2018; 15(12): 731–747.
10. Coulier F, Kumar R, Ernst M et al. Human trk oncogenes activated by point mutation, in-frame deletion, and duplication of the tyrosine kinase domain. Mol Cell Biol 1990; 10(8): 4202–4210.
11. Tacconelli A, Farina AR, Cappabianca L et al. Alternative TrkAIII splicing: a potential regulated tumor-promoting switch and therapeutic target in neuroblastoma. Future Oncol 2005; 1(5): 689–698.
12. Vaishnavi A, Le AT, Doebele RC. TRKing down an old oncogene in a new era of targeted therapy. Cancer Discov 2015; 5(1): 25–34.
13. Zehir A, Benayed R, Shah RH et al. Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nat Med 2017; 23(6): 703–713.
14. Prabhakaran N, Guzman MA, Navalkele P et al. Novel TLE4-NTRK2 fusion in a ganglioglioma identified by array-CGH and confirmed by NGS: potential for a gene targeted therapy. Neuropathology 2018; 38(4): 380.
15. Qaddoumi I, Orisme W, Wen J et al. Genetic alterations in uncommon low-grade neuroepithelial tumors: BRAF, FGFR1, and MYB mutations occur at high frequency and align with morphology. Acta Neuropathol 2016; 131(6): 833–845.
16. Milione M, Ardini E, Christiansen J et al. Identification and characterization of a novel SCYL3-NTRK1 rearrangement in a colorectal cancer patient. Oncotarget 2017; 8(33): 55353–55360.
17. Vaishnavi A, Capelletti M, Le AT et al. Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer. Nat Med 2013; 19(11): 1469–1472.
18. Tognon C, Garnett M, Kenward E et al. The chimeric protein tyrosine kinase ETV6-NTRK3 requires both Ras-Erk1/2 and PI3-kinase-Akt signaling for fibroblast transformation. Cancer Res 2001; 61: 8909–8916.
19. Pulciani S, Santos E, Lauver AV et al. Oncogenes in solid human tumours. Nature 1982; 300(5892): 539–542.
20. Drilon A, Siena S, Ou SI et al. Safety and antitumor activity of the multitargeted Pan-TRK, ROS1, and ALK inhibitor entrectinib: combined results from two phase I trials (ALKA-372-001 and STARTRK-1). Cancer Discov 2017; 7(4): 400–409.
21. Amatu A, Sartore-Bianchi A, Siena S. NTRK gene fusions as novel targets of cancer therapy across multiple tumour types. ESMO Open 2016; 1(2): e000023.
22. Tognon C, Knezevich SR, Huntsman D et al. Expression of the ETV6-NTRK3 gene fusion as a primary event in human secretory breast carcinoma. Cancer Cell 2002; 2(5): 367–376.
23. Skalova A, Vanecek T, Sima R et al. Mammary analogue secretory carcinoma of salivary glands, containing the ETV6-NTRK3 fusion gene: a hitherto undescribed salivary gland tumor entity. Am J Surg Pathol 2010; 34: 599–608.
24. Knezevich SR, McFadden DE, Tao W et al. A novel ETV6-NTRK3 gene fusion in congenital fibrosarcoma. Nat Genet 1998; 18(2): 184–187.
25. Knezevich SR, Garnett MJ, Pysher TJ et al. ETV6-NTRK3 gene fusions and trisomy 11 establish a histogenetic link between mesoblastic nephroma and congenital fibrosarcoma. Cancer Res 1998; 58: 5046–5048.
26. Wai DH, Knezevich SR, Lucas T et al. The ETV6-NTRK3 gene fusion encodes a chimeric protein tyrosine kinase that transforms NIH3T3 cells. Oncogene 2000; 19(7): 906–915.
27. Eguchi M, Eguchi-Ishimae M, Tojo A et al. Fusion of ETV6 to neurotrophin-3 receptor TRKC in acute myeloid leukemia with t(12;15)(p13;q25). Blood 1999; 93(4): 1355–1363.

28. Kralik JM, Kranewitter W, Boesmueller H et al. Characterization of a newly identified ETV6-NTRK3 fusion transcript in acute myeloid leukemia. Diagn Pathol 2011; 6(1): 19.

29. Church AJ, Calicchio ML, Nardi V et al. Recurrent EML4-NTRK3 fusions in infantile fibrosarcoma and congenital mesoblastic nephroma suggest a revised testing strategy. Mod Pathol 2018; 31(3): 463–473.

30. Lezcano C, Shoushtari AN, Ariyan C et al. Primary and metastatic melanoma with NTRK fusions. Am J Surg Pathol 2018; 42(8): 1052–1058.

31. Pietrantonio F, Di Nicolantonio F, Schrock AB et al. ALK, ROS1, and NTRK rearrangements in metastatic colorectal cancer. J Natl Cancer Inst 2017; 109(12): djx089.

32. Cocco E, Benhamida J, Middha S et al. Colorectal carcinomas containing hypermethylated MLH1 promoter and wild-type BRAF/KRAS are enriched for targetable kinase fusions. Cancer Res 2019; 79(6): 1047–1053.

33. Drilon A, Laetsch TW, Kummar S et al. Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children. N Engl J Med 2018; 378(8): 731–739.

34. Demetri GD, Paz-Ares A, Farago AF et al. Efficacy and safety of entrectinib in patients with NTRK fusion-positive (NTRK-fp) tumors: pooled analysis of STARTRK-2, STARTRK-1 and ALKA-372-001. Ann Oncol 2018; 29(Suppl 8): mdy424.017.

35. FDA Approves Larotrectinib for Solid Tumors with NTRK Gene Fusions 2018. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211710s000lbl.pdf (June 2019, date last accessed)

36. Tatematsu T, Sasaki H, Shimizu S et al. Investigation of neurotrophic tyrosine kinase receptor 1 fusions and neurotrophic tyrosine kinase receptor family expression in non-small-cell lung cancer and sensitivity to AZD7451 in vitro. Mol Clin Oncol 2014; 2(5): 725–730.

37. Chiang S, Cotzia P, Hyman DM et al. NTRK fusions define a novel uterine sarcoma subtype with features of fibrosarcoma. Am J Surg Pathol 2018; 42(6): 791–798.

38. Rudzinski ER, Lockwood CM, Stohr BA et al. Pan-Trk immunohistochemistry identifies NTRK rearrangements in pediatric mesenchymal tumors. Am J Surg Pathol 2018; 42(7): 927–935.

39. Hechtman JF, Benayed R, Hyman DM et al. Pan-Trk immunohistochemistry is an efficient and reliable screen for the detection of NTRK fusions. Am J Surg Pathol 2017; 41(11): 1547–1551.

40. Potts SJ, Dean EJ, Polikoff J et al. Detecting NTRK, ROS1, and ALK gene fusions in gastrointestinal tumor patients. J Clin Oncol 2017; 35(4): Suppl 619).

41. Murphy DA, Ely HA, Shoemaker R et al. Detecting gene rearrangements in patient populations through a 2-step diagnostic test comprised of rapid IHC enrichment followed by sensitive next-generation sequencing. Appl Immunohistochem Mol Morphol 2017; 25(7): 513–523.

42. Doebele RC, Davis LE, Vaishnavi A et al. An oncogenic NTRK fusion in a patient with soft-tissue sarcoma with response to the tropomyosin-related kinase inhibitor LOXO-101. Cancer Discov 2015; 5(10): 1049–1057.

43. Marchio C, Dowsett M, Reis-Filho JS. Revisiting the technical validation of tumour biomarker assays: how to open a Pandora's box. BMC Med 2011; 9: 41.

44. Negri T, Tamborini E, Dagrada GP et al. TRK-A, HER-2/neu, and KIT expression/activation profiles in salivary gland carcinoma. Transl Oncol 2008; 1(3): 121–128.

45. Yu X, Liu L, Cai B et al. Suppression of anoikis by the neurotrophic receptor TrkB in human ovarian cancer. Cancer Sci 2008; 99(3): 543–552.

46. Wadhwa S, Nag TC, Jindal A et al. Expression of the neurotrophin receptors Trk A and Trk B in adult human astrocytoma and glioblastoma. J Biosci 2003; 28(2): 181–188.

47. Farago AF, Le LP, Zheng Z et al. Durable clinical response to entrectinib in NTRK1-rearranged non-small cell lung cancer. J Thorac Oncol 2015; 10(12): 1670–1674.

48. Skalova A, Vanecek T, Simpson RH et al. Mammary analogue secretory carcinoma of salivary glands: molecular analysis of 25 ETV6 gene rearranged tumors with lack of detection of classical ETV6-NTRK3 fusion transcript by standard RT-PCR: report of 4 cases harboring ETV6-X gene fusion. Am J Surg Pathol 2016; 40: 3–13.

49. Reis-Filho JS, Natrajan R, Vatcheva R et al. Is acinic cell carcinoma a variant of secretory carcinoma? A FISH study using ETV6'split apart' probes. Histopathology 2008; 52(7): 840–846.

50. Greco A, Miranda C, Pierotti MA. Rearrangements of NTRK1 gene in papillary thyroid carcinoma. Mol Cell Endocrinol 2010; 321(1): 44–49.

51. Russell JP, Powell DJ, Cunnane M et al. The TRK-T1 fusion protein induces neoplastic transformation of thyroid epithelium. Oncogene 2000; 19(50): 5729–5735.

52. Frattini V, Trifonov V, Chan JM et al. The integrated landscape of driver genomic alterations in glioblastoma. Nat Genet 2013; 45(10): 1141–1149.

53. Bourgeois JM, Knezevich SR, Mathers JA, Sorensen PH. Molecular detection of the ETV6-NTRK3 gene fusion differentiates congenital fibrosarcoma from other childhood spindle cell tumors. Am J Surg Pathol 2000; 24(7): 937–946.

54. Del Castillo M, Chibon F, Arnould L et al. Secretory breast carcinoma: a histopathologic and genomic spectrum characterized by a joint specific ETV6-NTRK3 gene fusion. Am J Surg Pathol 2015; 39(11): 1458–1467.

55. Diallo R, Tognon C, Knezevich SR et al. Secretory carcinoma of the breast: a genetically defined carcinoma entity. Verh Dtsch Ges Pathol 2003; 87: 193–203.

56. Kim J, Kim S, Ko S et al. Recurrent fusion transcripts detected by whole-transcriptome sequencing of 120 primary breast cancer samples. Genes Chromosomes Cancer 2015; 54(11): 681–691.

57. Beadling C, Wald AI, Warrick A et al. A multiplexed amplicon approach for detecting gene fusions by next-generation sequencing. J Mol Diagn 2016; 18(2): 165–175.

58. Conde E, Caminoa A, Dominguez C et al. Aligning digital CD8(+) scoring and targeted next-generation sequencing with programmed death ligand 1 expression: a pragmatic approach in early-stage squamous cell lung carcinoma. Histopathology 2018; 72(2): 270–284.

59. Pavlick D, Schrock AB, Malicki D et al. Identification of NTRK fusions in pediatric mesenchymal tumors. Pediatr Blood Cancer 2017; 64(8): e26433.

60. Geiss GK, Bumgarner RE, Birditt B et al. Direct multiplexed measurement of gene expression with color-coded probe pairs. Nat Biotechnol 2008; 26(3): 317–325.

61. Tao JJ, Schram AM, Hyman DM. Basket studies: redefining clinical trials in the era of genome-driven oncology. Annu Rev Med 2018; 69(1): 319–331.

62. Laetsch TW, DuBois SG, Mascarenhas L et al. Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study. Lancet Oncol 2018; 19(5): 705–714.

63. Hong DS, Kummar S, Farago AF et al. Larotrectinib efficacy and safety in adult TRK fusion cancer patients. J Clin Oncol 2019; 37(Suppl 15): 3122.

64. Drilon AE, DuBois SG, Farago AF et al. Activity of larotrectinib in TRK fusion cancer patients with brain metastases or primary central nervous system tumors. J Clin Oncol 2019; 37(Suppl 15): 2006.

65. Siena S, Doebele RC, Tsang Shaw A et al. Efficacy of entrectinib in patients (pts) with solid tumors and central nervous system (CNS) metastases: integrated analysis from three clinical trials. J Clin Oncol 2019; 37(Suppl 15): 3017.

66. Drilon A, Nagasubramanian R, Blake JF et al. A next-generation TRK kinase inhibitor overcomes acquired resistance to prior TRK kinase inhibition in patients with TRK fusion-positive solid tumors. Cancer Discov 2017; 7(9): 963–972.

67. Russo M, Misale S, Wei G et al. Acquired resistance to the TRK inhibitor entrectinib in colorectal cancer. Cancer Discov 2016; 6(1): 36–44.

68. Drilon A, Li G, Dogan S et al. What hides behind the MASC: clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC). Ann Oncol 2016; 27(5): 920–926.

69. Drilon A, Ou SI, Cho BC et al. Repotrectinib (TPX-0005) is a next-generation ROS1/TRK/ALK inhibitor that potently inhibits ROS1/TRK/ALK solvent-front mutations. Cancer Discov 2018; 8(10): 1227–1236.

70. National Comprehensive Cancer Network®. NCCN Guidelines Version 5.2019 - Non-Small Cell Lung Cancer. In NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). NCCN Evidence Blocks™, Version 5.2019.